Page 17 - Athersys Inc News Today

The Cleveland-based regenerative medicine company also is making changes to its executive team in a restructuring plan that it said is designed to 'reduce costs and prioritize lead clinical programs.'

Athersys Inc. (ATHX) has initiated a restructuring plan after a study disappointed while cash reserves are dwindling.

Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs […]

Stock Analysts’ upgrades for Wednesday, June 1st: Applied Therapeutics (NASDAQ:APLT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 target price on the stock. According to Zacks, “Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet […]

Analysts’ new coverage for Tuesday, May 31st: The Goldman Sachs Group, Inc. initiated coverage on shares of ABN AMRO Bank (OTCMKTS:AAVMY). The firm issued a neutral rating and a €13.25 ($14.25) price target on the stock. StockNews.com began coverage on shares of Acme United (NYSE:ACU). StockNews.com issued a hold rating on the stock. Berenberg Bank […]

Press release content from Business Wire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation.

Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs […]

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market by Product Type, Material, Application and End user (Hospitals, Ambulatory Surgical Centers, and Others: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.The regenerative medicine market...

Athersys has been focused on developing a viable treatment for stroke for nearly 20 years. Read more to find out if now a good time to buy ATHX stock.